Why regenerative medicine practices consider SoftWave
Your existing patient base is often already comfortable with cash-pay, non-traditional treatment options — which removes one of the bigger adoption hurdles other specialties face when introducing something new.
SoftWave TRT is FDA-cleared for connective tissue activation and related musculoskeletal indications on its own merits; we don't position it as a stem-cell therapy or make regenerative claims beyond what's actually cleared. See the SoftWave TRT page for the precise, supportable claims.
Patient population
- Existing cash-pay patients open to non-invasive technology
- Patients seeking non-surgical options for chronic musculoskeletal complaints
- Patients already receiving other non-invasive regenerative-adjacent care
- Patients specifically researching advanced shockwave technology
Appropriateness for any individual patient is always a clinical decision made by the treating provider.
How it fits your workflow
SoftWave can be introduced alongside your existing service menu as an additional non-invasive option — many practices find their patient education process is already well-suited to introducing a technology like this.
Regenerative Medicine-specific FAQ
No. We don't make stem-cell or regenerative-outcome claims beyond SoftWave TRT's actual FDA-cleared indications. See the SoftWave TRT page for exactly what is and isn't claimed.
Many practices offer it alongside their existing menu — the specifics depend on your services and are worth discussing directly.